Top 10 US Biotechnology Companies By Revenues

As shared earlier, Biopharmaceutical industry landscape has changed significantly in the last 15 years. Currently, five Biotechnology companies are part of the top 15 Biopharmaceuticals club. For an industry to achieve this feat in such a short period is commendable. This meteoric rise of Biotechnology companies started in the year 2011.

Our analysis confirms this phenomenal rise – from mere 4% share of the overall biopharmaceutical market, biotechnology companies today contribute 29% to the overall Biopharmaceutical revenues. 

Initially laughed off as one drug phenomenon, Biotechnology companies have challenged the well tested “large molecule” business model of Pharmaceutical companies.

Currently, there are 47 Biotechnology companies in the U.S. with revenues more than $50 Million. These companies had a combined revenues of $122 billion during 2016.

Depending upon the business model, Biotechnology companies can be classified as product companies, subscription companies, and service companies. 

  • Biotechnology product companies offer pharmaceutical drug products that are manufactured in, extracted from or semi-synthesized from biological sources.
  • Subscription-based companies develop genome databases, which can be used to develop medicinal drugs. 
  • Service companies offer solutions based on a common technology or generic tool of other large pharmaceutical or biopharmaceutical companies

In this report, we will look at the top-10 Biotechnology companies in the US by their 2016 revenues. We will also look at the revenues, year-on-year (YoY) revenue growth, net profits, and net profit margin of the top-10 companies in the Biotechnology sector. For any comments/suggestions reach out to @pharavi

US Top-10 Biotechnology Companies Revenues and Profits

The top-10 Biotechnology companies in the US by 2016 revenues are Gilead Sciences Inc, Abbvie Inc., Amgen Inc, Biogen Inc., Celgene Corp, Regeneron Pharmaceuticals Inc, Alexion Pharmaceuticals Inc, Vertex Pharmaceuticals Inc, United Therapeutics Corp, and Biomarin Pharmaceutical Inc. 

Top 10 U.S. Biotechnology Companies By 2016 Revenues

The revenues and profits details of these companies are as follows:

1. Gilead Sciences Inc.

Gilead Sciences, Inc., is ranked no. 1 in the ‘Top 10 U.S. Biotechnology Companies By 2016 Revenues’. Gilead Sciences is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. Its products include AmBisome, Atripla, Cayston, Complera/Eviplera, Descovy, Emtriva, Epclusa, Genvoya, Harvoni, Hepsera, Letairis, Odefsey, Ranexa, Sovaldi, Stribild, Truvada, Tybost, Vemlidy, Viread, Vitekta and Zydelig. The Company’s areas of focus include HIV; liver diseases, such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection; hematology/oncology; cardiovascular, and inflammation/respiratory diseases.

Gilead Sciences generated $30.4 billion of revenues during 2016, down -6.9% YoY, from $32.6 billion in 2015. Gilead Sciences reported a net income of $13.5 billion during 2016 and the net profit margin was 44.4%. Gilead Sciences revenues, revenue growth, net income, and net profit margins for the past five years are presented in the diagram below.

Gilead Revenues And Profits Analysis FY' 2012-2016

2. Abbvie Inc.

Abbvie Inc (Abbvie) is ranked no. 2 in the ‘Top 10 U.S. Biotechnology Companies By 2016 Revenues’. Abbvie is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of Biopharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson’s disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.

Abbvie generated $25.6 billion of revenues during 2016, up 12.2% YoY, from $22.9 billion in 2015. Abbvie reported a net income of $6.0 billion during 2016 and the net profit margin was 23.2%. Abbvie revenues, revenue growth, net income, and net profit margins for the past five years are presented in the diagram below.

Abbvie Revenues And Profits Analysis FY' 2012-2016

3. Amgen Inc.

Amgen Inc (Amgen) is ranked no. 3 in the ‘Top 10 U.S. Biotechnology Companies By 2016 Revenues’ list. Amgen is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. The Company operates in the human therapeutics segment. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Amgen generated $23.0 billion of revenues during 2016, up 6.1% YoY, from $21.7 billion in 2015. Amgen reported a net income of $7.7 billion during 2016 and the net profit margin was 33.6%. Amgen revenues, revenue growth, net income, and net profit margins for the past five years are presented in the diagram below.

Amgen Revenues And Profits Analysis FY' 2012-2016

4. Biogen Inc.

Biogen Inc. (Biogen) is ranked no. 4 in the ‘Top 10 U.S. Biotechnology Companies By 2016 Revenues’ list. Biogen is a biopharmaceutical company. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). The Company also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin’s lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies.

Biogen generated $11.4 billion of revenues during 2016, up 6.4% YoY, from $10.8 billion in 2015. Biogen reported a net income of $3.7 billion during 2016 and the net profit margin was 32.3%. Biogen revenues, revenue growth, net income, and net profit margins for the past five years are presented in the diagram below.

Biogen Revenues And Profits Analysis FY' 2012-2016

5. Celgene Corp.

Celgene Corp is ranked no. 5 in the ‘Top 10 U.S. Biotechnology Companies By 2016 Revenues’ list. Celgene is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuroinflammation. The Company’s commercial stage products include REVLIMID (lenalidomide), POMALYST/IMNOVID (pomalidomide), OTEZLA (apremilast), ABRAXANE (paclitaxel albumin-bound particles for injectable suspension), VIDAZA, azacitidine for injection (generic version of VIDAZA) and THALOMID (thalidomide). Its clinical trial activity includes trials across the disease areas of hematology, solid tumors, and inflammation and immunology. The Company also markets ISTODAX, which is an epigenetic modifier.

Celgene generated $11.2 billion of revenues during 2016, up 21.3% YoY, from $9.3 billion in 2015. Celgene reported a net income of $2.0 billion during 2016 and the net profit margin was 17.8%. Celgene revenues, revenue growth, net income, and net profit margins for the past five years are presented in the diagram below.

Celgene Revenues And Profits Analysis FY' 2012-2016

6. Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc (Regeneron) is ranked no. 6 in the ‘Top 10 U.S. Biotechnology Companies By 2016 Revenues’ list. Regeneron is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases. The Company’s marketed products include EYLEA (aflibercept) Injection, Praluent (alirocumab) Injection, ARCALYST (rilonacept) Injection for Subcutaneous Use, Kevzara (sarilumab) Solution for Subcutaneous Injection and ZALTRAP (ziv-aflibercept) Injection for intravenous infusion.

Regeneron generated $4.9 billion of revenues during 2016, up 18.4% YoY, from $4.1 billion in 2015. Regeneron reported a net income of $0.9 billion during 2016 and the net profit margin was 18.4%. Regeneron revenues, revenue growth, net income, and net profit margins for the past five years are presented in the diagram below.

Regeneron Revenues And Profits Analysis FY' 2012-2016

7.  Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals Inc (Alexion) is ranked no. 7 in the ‘Top 10 U.S. Biotechnology Companies By 2016 Revenues’ list. Alexion is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Alexion Pharmaceuticals generated $3.1 billion of revenues during 2016, up 18.4% YoY, from $2.6 billion in 2015. Alexion Pharmaceuticals reported a net income of $0.4 billion during 2016 and the net profit margin was 12.9%. Alexion Pharmaceuticals revenues, revenue growth, net income, and net profit margins for the past five years are presented in the diagram below.

Alexion Revenues And Profits Analysis FY' 2012-2016

8. Vertex Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc (Vertex) is ranked no. 8 in the ‘Top 10 U.S. Biotechnology Companies By 2016 Revenues’ list. Vertex is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company’s marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene.

Vertex Pharmaceuticals generated $1.7 billion of revenues during 2016, up 64.9% YoY, from $1.0 billion in 2015. Vertex Pharmaceuticals reported a net income of -$0.1 billion during 2016 and the net profit margin was -6.6%. Vertex Pharmaceuticals revenues, revenue growth, net income, and net profit margins for the past five years are presented in the diagram below.

Vertex Revenues And Profits Analysis FY' 2012-2016

9. United Therapeutics Corp.

United Therapeutics Corp (United Therapeutics) is ranked no. 9 in the ‘Top 10 U.S. Biotechnology Companies By 2016 Revenues’ list. United Therapeutics, is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

United Therapeutics generated $1.6 billion of revenues during 2016, up 9.1% YoY, from $1.5 billion in 2015. United Therapeutics reported a net income of $0.7 billion during 2016 and the net profit margin was 44.6%. United Therapeutics revenues, revenue growth, net income, and net profit margins for the past five years are presented in the diagram below.

United Therapeutics Revenues And Profits Analysis FY' 2012-2016

10. Biomarin Pharmaceutical Inc. 

Biomarin Pharmaceutical Inc. (BioMarin Pharmaceutical) is ranked no. 10 in the ‘Top 10 U.S. Biotechnology Companies By 2016 Revenues’ list. BioMarin Pharmaceutical is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A).

Biomarin Pharmaceutical generated $1.1 billion of revenues during 2016, up 25.5% YoY, from $0.9 billion in 2015. Biomarin Pharmaceutical reported a net income of -$0.6 billion during 2016 and the net profit margin was -56.4%. Biomarin Pharmaceutical revenues, revenue growth, net income, and net profit margins for the past five years are presented in the diagram below.

Biomarin Revenues And Profits Analysis FY' 2012-2016


Our Research on the Top 3000 Companies in the US

All the analysis in this article is from our proprietary financial database of the top 3000 public companies in the US. We call it R&P Screener.

It helps investors and B2B sales & marketing professionals “quickly and easily” identify the following types of companies in any sector or industry:

  • High growth, medium growth, low growth, or negative revenue growth companies;
  • Highly profitable, moderately profitable, or loss-making companies;
  • Top-n (top-5, top-10, top-20 etc.) companies by revenues, revenue growth, net profits, net profit growth or net profit margin;
  • Mega, very large, large, or medium-size companies by their latest annual revenue.

Here are some brief insights about the US top 3000 companies from the R&P Screener (April 2017 Update):

  • The combined revenues of the US top 3000 companies were $14.49 trillion during 2016. The combined net income was $1.03 trillion.
  • There were 54 Mega (revenues greater than $50 billion), 239 Very Large (revenues between $10 and $50 billion), 1097 Large (revenues between $1 and $10 billion), and 1610 Medium (revenues between $50 million and $1 billion) during 2016.
  • There were 2224 companies (74.8% of the total) with positive net income and 756 companies (25.2% of the total) with negative net income during 2016.
  • There were 1985 companies (66.2% of the total) with a positive revenue growth and 1015 companies (33.8% of the total) with a negative revenue growth during 2015-16.
  • There were 1236 companies (41.2% of the total) with a positive net income growth and 800 companies (26.7% of the total) with a negative net income growth during 2015-16. For 964 companies (32.1% of the total), we could not compute net income growth because their net income was negative during 2015 or 2016.
  • California, Texas, New York, Illinois, and Massachusetts are the top five states in terms of the number of companies with headquarters locations. A total of 1309 companies (43.6% of the total) have headquarters in these states.

Notes

Fiscal Year versus the Calendar Year

The reported revenues and net income correspond to the fiscal year of the companies. If a company’s fiscal year ended in September 2016, then we report revenues for the twelve months period ending in September 2016. Similarly, if a company’s fiscal year ended in May 2016, then we report revenues for the twelve months period ending in May 2016.

Which companies are included in the R&P Screener?

  • R&P Screener includes US Companies listed in New York Stock Exchange (NYSE), Nasdaq, and Amex (now known as NYSE markets). These companies regularly file their quarterly (10-Q) and annual (10-K) reports with Securities and Exchange Commission (SEC) in the US. These companies were incorporated in the US and have headquarters in the US as well.
  • US companies that were founded in the US, but have headquarters outside the US are also included. These companies have headquarters outside the US due to taxation benefits, foreign governments incentives, proximity to customers, or some other reasons. Since more than 50% of the stocks of these companies are traded on US stock exchanges, they file 10-Ks and 10-Qs similar to the US-headquartered companies.
  • All the companies in the R&P Screener had revenues of more than $50 million in 2016

Which companies are not included in the R&P Screener?

  • US companies listed in OTC markets.
  • Private companies in the US.
  • Any companies delisted from NYSE, Nasdaq, or Amex stock exchanges. These companies may have been acquired, filed for bankruptcy, or may have become private entities.
  • Any foreign companies listed on US stock exchanges. These companies do not file 10-Q or 10-K. Instead, they provide their annual financial information in 20-F reports.

LEAVE A REPLY